EGFR and non-small cell lung carcinoma: In the pooled cohort, 283 patients with advanced NSCLC and PD-L1 expression ≥50% were treated with cemiplimab monotherapy, and 312 patients with advanced NSCLC and no EGFR, ALK, or ROS1 genomic aberrations were treated with cemiplimab plus chemotherapy (9, 10).